HAIFA, Israel--(BUSINESS WIRE)--July 15, 2004--Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a biotechnology company dedicated to the expansion of stem cells from umbilical cord blood to address a myriad of fatal illnesses, today announced that the Company has been invited to present at the 33rd Annual Meeting of the International Society for Experimental Hematology (ISEH) in New Orleans from July 17th to July 20th, 2004.

Poster presentation:
"Superiority of 3-D Stromal Cell Structure for the Proliferation
of Transplantable Hematopoietic Stem Cells"
Poster #179: Session 1 - Sunday: 4:15-6:00pm
Marriott Preservation Hall

The announcement of the Company's participation and presentation further signifies the importance of the progress of the Company's technology. Pluristem will demonstrate the superiority of a three-dimensional (3-D) culture, utilizing its proprietary PluriX(TM) bioreactor, over the conventional two-dimensional (2-D) culture used in most stem cell research for the expansion of stem cells. Pluristem scientists will provide critical data on the importance of the 3-D stromal cell culture and its superiority in supporting the expansion of hematopoietic stem cells (HSC). The company will present results proving the PluriX(TM) bioreactor system's ability to significantly expand HSC (over 100 fold).

Pluristem's core technology is designed to expand hematopoietic stem cells (HSC) from umbilical cord blood for bone marrow transplantations. The unique quality of the PluriX(TM) is its ability to create a 3-D microenvironment that closely resembles the structure and function of the body's bone marrow, where HSC expansion occurs in growth factor-free conditions (without the use of external cytokines).

Bone marrow transplants (BMT) offer an ultimate treatment for many blood and immune system diseases. HSC have the ability to evolve into different types of blood cells and are exclusively required to reconstitute the hematopoietic system following bone marrow transplantation. Today BMT using cord blood have achieved limited success due to the small volume of blood which can be collected from the umbilical cord. Using the 3-D PluriX(TM) bioreactor, one donation of HSC from cord blood will be expanded to quantities large enough for a number of adult transplants.

"Pluristem's invitation to present its findings at the ISEH conference reinforces the belief our technology holds in expanding stem cells in optimal environments for bone marrow transplantations and the potential for other applications in the field of hematology. Forums of this nature and the ability to demonstrate our findings generate continued exposure in the global scientific community," stated Dr. Mendi Ze'evi, CEO.

About ISEH

For more information about ISEH, please visit www.iseh.org .

About Pluristem www.pluristem.com

Pluristem is a biotechnology company dedicated to the development of stem cell expansion technology. The Company is concentrating on the expansion of cord blood hematopoietic stem cells (blood and immune system cells) to provide vital stem cell expansion services to blood banks and transplants centers in the U.S. and Europe.

Safe Harbor Statement

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing stem cell technology into a useful product which, among other things, can treat fatal illnesses and obtaining patent protection in the US and worldwide for our technology. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to complete its obligations under the stem cell license agreement, inability to finance the planned development of the technology, unforeseen technical difficulties in developing the stem cell technology, and challenges to or failure of our patent applications, which could among other things, delay or prevent product release or our ability to protect our products from competition. For further risk factors see the Company's 10-KSB filed with the SEC for our latest completed fiscal year.